Developed Technology vs IPR&D
Developed technology is commercially deployed at acquisition (RFR or MPEEM). IPR&D is technology under development held at indefinite life until resolved.
Introduction
Developed technology and In-Process Research and Development (IPR&D) are two distinct intangible asset classes that often appear together in technology-driven acquisitions. Developed technology is technology that is commercially deployed and generating cash flow at the acquisition date. IPR&D is technology under active development that has not yet reached commercial deployment. Under IFRS 3 (UK and global) and ASC 805 (US), both are separately identifiable intangibles when recognition criteria are met, but they are valued and treated differently — and the stage of development at the acquisition date is the critical fact that determines classification.
This page compares developed technology and IPR&D as intangible asset classes under IFRS 3 (UK and global) and ASC 805 (US). It sets out the recognition criteria, the typical valuation methods, the amortisation patterns, and the audit-defensibility considerations. The reader is assumed to be a valuer, M&A advisor, or financial controller working on PPA in a technology-rich deal.
TL;DR: Developed technology is technology that has reached commercial deployment and is generating cash flow at the acquisition date — valued using RFR or MPEEM, amortised over its useful life. IPR&D is technology in active development that has not yet been commercialised — valued using an asset-level multi-stage DCF (or cost approach where DCF cannot be supported), held at fair value as an indefinite-life intangible until the project either completes (becomes a finite-life developed-technology asset and starts amortising) or is abandoned (written off through impairment). The classification turns on stage of development at the acquisition date, not on the asset's eventual potential.
Developed Technology
Developed technology is technology — software, formulations, processes, designs, algorithms — that has reached commercial deployment and is generating cash flow at the acquisition date. The asset has been substantially completed: the development risk has materially resolved, the commercial release has happened (or is imminent), and the technology is contributing to the operating business's revenue base. Under IFRS 3 (UK and global) and ASC 805 (US), developed technology is separately identifiable when the technology is protected by contractual or legal rights (patents, trade secrets, copyrights), or where it is separable from the rest of the acquired business.
Recognition criteria
Under IFRS 3.IE39 (UK and global) and ASC 805-20-55 (US), developed technology is separately identifiable when:
- The technology arises from contractual or legal rights (patents, trade secrets, licences, copyrights), OR
- The technology is separable — it could be sold, licensed, or transferred independently of the rest of the acquired business
How developed technology is valued
The dominant methods are RFR and MPEEM, with the choice driven by whether the technology is the primary income generator of the acquired business:
- Relief from Royalty (RFR) — used when the technology has a comparable licensing market. Software, SaaS platforms, patented compounds, and licensed technology all suit RFR where royalty-rate benchmarks exist
- MPEEM — used when the technology is the primary income generator and no comparable royalty market exists (or where the licensing analogue is too stretched to support a defensible RFR). Common in proprietary platforms, custom-developed software, and technology that is unique to the acquired business
- Cost approach — used in narrow cases where neither RFR nor MPEEM can be supported, typically internally developed software with low strategic value
What you need to apply RFR or MPEEM to developed technology
- Revenue forecast attributable to the technology (RFR: at least the licensable portion; MPEEM: the full attributable revenue stream)
- Royalty-rate benchmarks (RFR): 3-5 comparable licensing transactions in the same industry vertical
- Contributing-asset inventory and CACs (MPEEM)
- Useful life supported by technology-lifecycle analysis (typical: 3-10 years for software; 5-15 years for patented or hardware technology)
- Tax rate and TAB factor where the buyer's jurisdiction permits tax amortisation
- Discount rate at WACC plus any technology-specific premium (often 100-300bps for SaaS / cloud, 200-500bps for early-stage or experimental technology)
Useful life and amortisation
Developed technology typically has a finite useful life capped by technology-lifecycle considerations: obsolescence, replacement risk, competitive substitution. Typical useful lives:
- SaaS / cloud software → 3-7 years
- On-premise enterprise software → 5-10 years
- Patented technology with protection horizon → period to patent expiry, capped at 12-15 years
- Custom-built proprietary platforms → 7-15 years depending on competitive substitution risk
Amortisation is typically straight-line under IAS 38.97 (UK and global) and ASC 350-30-35 (US), unless a different pattern better reflects the consumption of economic benefits.
A SaaS acquisition includes a developed-technology asset (the SaaS platform) that generates 100% of the company's revenue. Year-1 revenue attributable to the platform is £28m. RFR is applied with a 12% royalty rate (median of 8 comparable SaaS licensing transactions), projected over a 7-year useful life with 4% terminal decline. After-tax royalty stream is discounted at WACC + 200bps = 12.5%. Pre-TAB fair value is £20.4m; TAB factor at UK tax rates lifts the asset to £23.8m. Amortised straight-line over 7 years.
Defensibility profile
Developed technology valued under RFR is defensible when the royalty-rate benchmarks come from comparable transactions in the same industry vertical, with similar exclusivity terms and asset characteristics. Audit and regulator focus lands on (a) royalty-rate justification, (b) revenue attribution where the technology is one of several revenue drivers, and (c) useful-life assumption against technology-lifecycle evidence. Developed technology valued under MPEEM faces the same defensibility profile as customer-relationship MPEEM (contributing-asset inventory, CAC rates, discount-rate consistency).
Developed technology is commercially deployed and generating cash flow at the acquisition date. RFR is the default where royalty benchmarks exist; MPEEM where the technology is primary income generator without licensing analogues. Useful life is bounded by technology-lifecycle realism — audit teams challenge optimistic life assumptions.
In-Process Research and Development (IPR&D)
In-Process Research and Development is technology, formulations, designs, or scientific work that is under active development at the acquisition date but has not yet reached commercial deployment. The asset has not generated cash flow, the technical and commercial risks have not resolved, and the project's outcome is uncertain. Under IFRS 3 (UK and global) and ASC 805 (US), IPR&D is recognised as a separately identifiable intangible at acquisition with specific treatment that diverges from developed-technology accounting.
Recognition criteria
Under IFRS 3.21A (UK and global) and ASC 805-20-25 (US), IPR&D acquired in a business combination is recognised as an intangible asset separately from goodwill regardless of whether the asset would have been capitalised had it been developed internally. This is a deliberate divergence from IAS 38's normal capitalisation criteria — at acquisition, the IPR&D's fair value is captured as an intangible whether or not internal-development capitalisation would have applied.
How IPR&D is valued
The standard method is multi-stage DCF, recognising the probability-weighted cash flows of the project across its development stages:
- Project the cash flows the technology will generate if it reaches commercial deployment
- Apply probability weighting at each development stage — probability of technical success, probability of commercial success conditional on technical success, probability of regulatory approval (where relevant)
- Apply development costs that remain to be incurred to reach commercial deployment
- Discount at a rate that reflects the residual technical and commercial risk in the project — typically WACC plus a significant premium (300-800bps for late-stage development, 1,000bps+ for early-stage)
- Apply TAB where the buyer's jurisdiction permits tax amortisation post-completion
Where the DCF cannot be supported (very early stage, no defensible revenue projection), a cost approach is used — typically estimating what it would cost a market participant to recreate the IPR&D's current state, adjusted for the cost saving from acquiring it ready-made.
Subsequent treatment
IPR&D is treated specially after recognition. Under both IFRS 3 (UK and global) and ASC 805 (US), IPR&D is held as an indefinite-life intangible until the project either completes or is abandoned. While held as indefinite-life:
- It is not amortised
- It is tested annually for impairment under IAS 36 (UK and global) or ASC 350 (US)
- If the project completes and reaches commercial deployment, the IPR&D is reclassified as developed technology, a useful life is determined, and amortisation begins from the reclassification date
- If the project is abandoned, the carrying value is written off through impairment
A pharmaceutical acquisition includes an IPR&D asset — a clinical-stage compound at Phase II of development. Multi-stage DCF is applied: peak-sales revenue projected at £180m annually if the compound reaches market, probability-weighted at 35% (Phase II to approval probability based on industry data for the therapeutic class), discounted at WACC + 500bps to reflect residual technical and regulatory risk. Pre-TAB fair value is £42m; TAB factor at UK tax rates lifts the asset to £49m. Held as indefinite-life intangible, tested annually for impairment, reclassified to developed-technology asset (with 8-year amortisation) upon regulatory approval.
Defensibility profile
IPR&D is highly defensible when the probability weighting is supported by industry data and the residual risk premium in the discount rate is consistent with the stage of development. Audit focus lands on three areas: (a) the probability-weighting basis (is it sector-benchmarked or management-derived?), (b) the discount-rate premium relative to the project's stage, and (c) the subsequent-period impairment testing — whether the annual impairment test has identified deterioration that should reduce the carrying value.
The indefinite-life classification of IPR&D is a deliberate accounting choice in IFRS 3 (UK and global) and ASC 805 (US). It does not mean the asset has indefinite economic life — it means the asset is held at its acquisition-date fair value, untouched by amortisation, until the project's outcome resolves. Auditors check that the annual impairment test is being applied rigorously; stale IPR&D balances that have not moved despite project setbacks get flagged.
Side-by-Side Comparison
The table below sets out the practitioner's quick-reference view. Each row is a dimension of distinction.
| Criterion | Developed Technology | IPR&D (In-Process R&D) |
|---|---|---|
| Stage of development at acquisition | Commercially deployed; generating cash flow | Active development; not yet commercially deployed |
| Recognition criterion (IFRS 3 / ASC 805) | Contractual or legal rights, OR separable | Recognised regardless of internal-development capitalisation criteria |
| Dominant valuation method | RFR (where royalty benchmarks exist) or MPEEM (primary intangible) | Asset-level multi-stage DCF with probability weighting, or cost approach where DCF unsupportable |
| Discount rate premium | WACC + 100-300bps (SaaS) to + 500bps (early / experimental) | WACC + 300-800bps (late stage) to + 1,000bps+ (early stage) |
| Useful life at acquisition | Finite — typically 3-15 years | Indefinite — until project completes or is abandoned |
| Amortisation at acquisition | Yes — straight-line by default | No — held as indefinite-life until reclassification |
| Impairment testing pattern | Trigger-based under IAS 36 / ASC 350 | Annual impairment test mandatory while indefinite-life |
| Subsequent reclassification | Generally remains developed technology through life | Reclassified to developed technology on project completion; amortisation begins then |
| TAB applicability | Yes — applied to RFR or MPEEM result | Yes — applied to asset-level DCF or cost result; future tax benefits captured at acquisition |
| Typical magnitude in PPA | Often the largest technology-related intangible | Significant in pharma, life sciences, and high-R&D-intensity acquisitions |
| Audit focus | Royalty-rate justification, useful life, revenue attribution | Probability weighting, discount-rate premium, annual impairment test rigour |
| Common pitfall | Optimistic useful life; misattribution of revenue to multiple drivers | Probability weighting derived without sector benchmarks; stale impairment tests |
| Treatment under FRS 102 Section 18 (UK) | Recognition criteria tighter; finite life mandatory; max 10-year fallback | Capitalisation criteria of IAS 38.57 applied — most IPR&D not recognised separately |
| Disclosure required (IAS 38.118) | Material class; amortisation method and useful life disclosed | Material class; indefinite-life status and impairment testing approach disclosed |
| Where the assets connect | A successful IPR&D asset becomes developed technology at completion | A developed technology with planned major upgrade may carry an IPR&D component |
How the two assets relate over the project lifecycle
The two assets are not unrelated — they sit at different stages of the same technology lifecycle:
- At inception: No asset recognised. Internal R&D is expensed under IAS 38.54 (UK and global) and ASC 730 (US) until capitalisation criteria are met
- During development: IPR&D can only be recognised if acquired in a business combination — internal IPR&D is generally not capitalised (IAS 38 has narrow criteria; ASC 730 expenses development costs in the US)
- At commercial deployment: Acquired IPR&D is reclassified to developed technology. Internal development that met capitalisation criteria becomes an internally-generated developed-technology intangible
- Through useful life: Both classes (acquired and internal) are amortised over their useful life
- At end of life: Carrying value reaches zero or is written off through impairment
In a single acquisition, the buyer often inherits both — completed products as developed technology and the next generation as IPR&D. The PPA must separate the two, value each appropriately, and document the boundary between them.
Developed technology and IPR&D are two stages of the same lifecycle. The classification turns on whether commercial deployment has happened by the acquisition date. Misclassification has a direct impact on the amortisation pattern, the impairment regime, and the carrying value's path through future reporting periods.
FAQ
When does IPR&D become developed technology?
When the project reaches commercial deployment. The trigger is the start of the technology's commercial use — first revenue, first sale, first deployment to a paying customer, or regulatory approval where applicable (pharma, medical devices). On the trigger date, the IPR&D is reclassified to developed technology, a useful life is determined based on technology-lifecycle considerations, and amortisation begins from that date. The carrying value at reclassification is the IPR&D's acquisition-date fair value adjusted for any impairment recognised in the interim.
Is internal IPR&D recognised as an asset?
Generally no. Under IAS 38.54 (UK and global), research costs are expensed, and development costs are only capitalised when the strict six-criteria test in IAS 38.57 is met. Under ASC 730 (US), most R&D is expensed as incurred. The exception is IPR&D acquired in a business combination — IFRS 3 (UK and global) and ASC 805 (US) override the normal capitalisation rules and require recognition of acquired IPR&D regardless of whether internal-development capitalisation would apply. This creates an asymmetry: the same project recognised at acquisition might never have been capitalised internally.
What discount rate premium is appropriate for IPR&D?
The premium reflects residual technical and commercial risk in the project. Late-stage IPR&D (Phase III pharma, near-commercial software, completed designs awaiting regulatory clearance) typically attracts a premium of 300-500bps above WACC. Mid-stage IPR&D attracts 500-800bps. Early-stage IPR&D (Phase I or II pharma, proof-of-concept software, experimental designs) attracts 800-1,500bps or more. The defensible position is to anchor the premium to comparable industry observations and document the stage-of-development reasoning.
How are probability weights set in multi-stage IPR&D DCF?
Probability weights at each stage are derived from industry data on the historical conversion rates from one stage to the next. For pharma, the standard reference is sector studies that show, for example, Phase II to approval rates of 30-40% in oncology, 50-60% in dermatology. For software and other technology, the data is thinner — practitioners use management's track record on similar projects, comparable acquisition cases, and conservative bounds. Management-derived weights without external anchor are the most common audit challenge.
Is IPR&D tested for impairment annually?
Yes, under both IAS 36 (UK and global) and ASC 350 (US) while it is classified as indefinite-life. The annual test compares the asset's recoverable amount to its carrying value. Recoverable amount is the higher of (a) fair value less costs of disposal and (b) value in use. Where the project has experienced setbacks — delayed milestones, regulatory feedback requiring rework, competitive substitution risk — these are typically indicators that recoverable amount has fallen below carrying value and an impairment may be required. Stale IPR&D balances that have not moved despite known project setbacks attract sharp audit attention.
What happens when IPR&D is abandoned?
The carrying value is written off through impairment to nil. The write-off is recognised in profit or loss in the period the abandonment decision is made (or earlier, if impairment indicators were present in a prior period). Abandonment is a recognition event — auditors test the timing carefully because delaying recognition smooths reported profits, and the standards do not permit deferral once the abandonment decision is made.
Does TAB apply to IPR&D at acquisition?
Yes, in jurisdictions where the acquired IPR&D will be eligible for tax amortisation post-completion. The TAB factor is applied to the IPR&D's acquisition-date fair value at acquisition, even though tax amortisation will not begin until the project completes and amortisation commences. This treats the future tax shield's present value as part of the acquisition-date fair value, consistent with the market-participant principle of IFRS 13 (UK and global) and ASC 820 (US).
What is the FRS 102 treatment of IPR&D?
Under FRS 102 Section 18 (UK), the recognition criteria for intangibles are tighter and indefinite-life classification is not permitted. Acquired IPR&D is treated under IAS 38's normal capitalisation criteria — most projects fail the six-criteria test in IAS 38.57 and are therefore not recognised separately under FRS 102. Where the entity has a choice of framework, IFRS 3 (UK and global) and ASC 805 (US) recognition is materially broader for IPR&D than FRS 102. FRS 102 transitions sometimes require derecognition of IPR&D that was previously recognised under IFRS.
When to Seek Expert Support
Developed-technology vs IPR&D classification is routine when the boundary is clear and the underlying technology is well-documented. It becomes technically demanding where (a) the technology sits at the boundary between in-development and deployed (early-customer-trial phase, soft-launch period, pilot deployments), (b) the multi-stage DCF probability weights are contested in audit, (c) the IPR&D's annual impairment test is challenged after project setbacks, or (d) FRS 102 transition raises recognition questions.
Opagio's Asset Valuator module (within Opagio Intangibles) supports both asset-level developed-technology RFR / MPEEM and asset-level IPR&D multi-stage DCF valuations, captures the stage-of-development evidence in the Value Drivers Register, and produces the audit-trail documentation that supports each classification and reclassification event through the project lifecycle.
For technology-rich acquisitions or where IPR&D is the dominant value driver, the right pattern is to automate the mechanical work and have a qualified specialist review the probability weights, discount-rate premium, and stage-of-development classification before sign-off.
Book a demo: See how Asset Valuator handles a technology-driven PPA with both developed technology and IPR&D recognised, valued, and tracked through the project lifecycle. Book a demo or speak to our team.
Related Glossary Terms
Learn More
Ready to Value Your Intangible Assets?
Use Opagio's valuation tools to apply these methods to your own business.